STRATA Skin Sciences gains approval for new device in Japan By Investing.com

HORSHAM, Penn. – STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company, announced today the Japanese Ministry of Health, Labor and Welfare has approved its latest dermatological device, the XTRAC Momentum™ 1.0. This approval marks the introduction of the device to the Japanese market, following its initial U.S. launch in early 2022.

The XTRAC Momentum™ 1.0 is an excimer laser designed for treating skin conditions such as psoriasis, eczema, and vitiligo. It boasts higher power and a faster repetition rate compared to previous models. Additionally, it features an updated user interface and a sleek design aimed at enhancing the treatment experience.

STRATA has established a commercial partnership with JMEC Co., Ltd., a longstanding strategic partner in Japan, to distribute the new device. Over 300 hospitals and private dermatology clinics in Japan currently use STRATA’s excimer devices. Dr. Dolev Rafaeli, President and CEO of STRATA, expressed optimism about the device’s potential impact on the Japanese dermatology market.

The XTRAC® technology by STRATA allows for targeted UVB light therapy, which is applicable for both adult and pediatric patients. STRATA’s product line also includes VTRAC® lamp systems and the TheraClear®X Acne Therapy System.

The company operates in the United States through its Partnership Program, which offers a per-treatment fee structure as opposed to equipment purchase. This program includes installation, on-site training, equipment service and maintenance, dedicated account management, and co-op advertising support.

The press release from STRATA Skin Sciences also contained forward-looking statements regarding the company’s plans and expectations. These statements reflect the company’s current views with respect to future events and are subject to various risks, uncertainties, and assumptions. STRATA urges investors to review its SEC disclosures for a more complete understanding of these factors.

The information provided is based on a press release statement from STRATA Skin Sciences, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.